Draft monograph: PT-141 (bremelanotide) — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. Regulatory status is stated without naming the jurisdiction — arising from DRAFT-PT-141-MONOG/007. Every regulatory status statement now names the authority, states the date on which the status was verified, and is recorded per jurisdiction rather than as a single global assertion.
2. Effect estimates are given without naming the comparator — arising from DRAFT-PT-141-MONOG/009. The comparator is now stated in every outcome row, and estimates against different comparators are reported in separate tables with the comparator named in the table caption.
3. The population to which the headline estimate applies is not stated with the estimate — arising from DRAFT-PT-141-MONOG/006. Every headline estimate now carries a one-line statement of the population in which it was observed, and the full eligibility criteria are reported in the included-studies table rather than only in the source.
4. The recorded evidence gaps omit outcomes a reader would consider material — arising from DRAFT-PT-141-MONOG/004. The evidence-gap section is now derived from the anchor and decision-relevant outcomes for the indication, and any such outcome measured by no contributing trial is recorded as not measured rather than omitted.
5. The analytical section assumes a reference standard that is not generally available — arising from DRAFT-PT-141-MONOG/011. The analytical section now states whether a reference standard is in general circulation for this compound and, where it is not, states which determinations remain possible and which become qualitative. A content figure obtained without a reference standard…
6. Absence of evidence is presented in a form a reader will take as negative evidence — arising from DRAFT-PT-141-MONOG/005. A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at…
7. A purity figure from a certificate is quoted as though it were a content figure — arising from DRAFT-PT-141-MONOG/002. Purity and content are now reported in separate rows with separate definitions, and the monograph states that a purity figure sets no bound on content and that a content figure requires a determination against a standard of assigned content.
8. The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-PT-141-MONOG/014. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
9. Quantitative claims are reproduced without the method that produced them — arising from DRAFT-PT-141-MONOG/003. Every quantitative claim now carries the determination that produced it at the point of use, and figures obtained by non-comparable methods are no longer presented in the same row or sentence.
10. A near-isobaric analogue is not distinguished by the identity determination described — arising from DRAFT-PT-141-MONOG/013. The analytical section now states the resolving power required to discriminate the pair, names the pair explicitly, and records that an identity claim made below that resolution is not conformant with the identity standard.
11. Where the compound is a glucagon-like peptide-1 receptor agonist, the cardiovascular outcome… — arising from DRAFT-PT-141-MONOG/008. Cardiovascular outcomes are now an assessed outcome with their own certainty rating in every monograph for which a dedicated cardiovascular outcome trial of that compound has reported, and are recorded as not assessed elsewhere.
12. The analytical section is longer than the clinical assessment it accompanies — arising from DRAFT-PT-141-MONOG/016. The analytical section is reduced to compound-specific content and cross-references the relevant standards for the general procedure, which shortens it substantially without removing what is not available elsewhere.
13. The compound is supplied under names the monograph does not list — arising from DRAFT-PT-141-MONOG/017. The synonym list is extended to include every name the Institute can evidence from a document it holds, each recorded with its source. Names asserted without a supporting document are not added, and the distinction is stated at the head of the list.
14. Adverse event frequencies are given without the denominator or the exposure period — arising from DRAFT-PT-141-MONOG/015. Every reported frequency now carries the number of participants, the number of events and the exposure period, and comparator-arm figures are reported alongside rather than in a separate table.
15. The preclinical section is extensive and the clinical section is not — arising from DRAFT-PT-141-MONOG/001. The preclinical section is reduced in length, placed after the clinical assessment rather than before it, and opens with a standing statement that an effect observed in an animal model is not a clinical outcome and does not support a certainty rating.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.